Updated guidelines for CPR following drowning; former state senator defrauds HRSA to pay for wedding; first hangover treatment – Morning Medical Update

Author(s):

Austin Littrell

Key Takeaways

Updated CPR guidelines for drowning stress oxygen administration and rescue breaths, addressing a leading cause of death in young children.
Katrina Robinson, former Tennessee state senator, was resentenced for wire fraud involving misused federal grants for personal expenses.
Sen-Jam Pharmaceutical's Phase II trial for SJP-001, a potential FDA-approved hangover prevention treatment, targets inflammatory responses from alcohol consumption.

The top news stories in medicine today.

AHA and AAP update guidelines for CPR following drowning

The American Heart Association (AHA) and American Academy of Pediatrics (AAP) worked together to update the AHA guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care following drowning. Drowning is the leading cause of death for children 1 to 4 years of age in the U.S., and the second leading cause of death in children aged 5 to 14 years. The guidelines recommend oxygen administration when available and rescue breaths as part of CPR, which can be initiated with breathing or compressions. Learn more about the updated guidelines here.

Former state senator resentenced and fined

A federal judge resentenced Katrina Robinson, 43, former Tennessee state senator and founder and director of The Healthcare Institute (THI), to time served and imposed an additional fine of $48,600 for misrepresentations made to the Health Resources and Services Administration (HRSA). Between 2015 and 2019, THI received more than $2.2 million in federal grants from HRSA. In 2021, a jury found Robinson guilty of two counts of wire fraud in connection with transfers made from THI’s operating account for personal wedding expenditures. She was also found guilty of two counts of wire fraud for fraudulent misrepresentations made to HRSA while completing Annual Performance Review forms.

Phase II trial begins for world’s first FDA-approved hangover prevention treatment

Sen-Jam Pharmaceutical, a New York-based company, announced the start of a Phase II trial for its hangover prevention therapy, SJP-001. The company says the compound has the potential to become the world’s first U.S. Food and Drug Administration (FDA)-approved hangover prevention. The treatment, a combination of naproxen and fexofenadine, is intended to reduce the inflammatory response following alcohol consumption, which leads to a hangover. A previous study found that the compound was able to reduce hangover symptoms like headaches, nausea and dizziness. Clinical Trials Arena has more.